How Much Does Deep Brain Stimulation (DBS) Cost?

The total cost of deep brain stimulation surgery, including the device, hospital stay, and first year of follow-up, averages roughly $48,000 in inflation-adjusted U.S. dollars, though the range is wide enough that some patients pay considerably more or less depending on their country, hospital, insurance, and the condition being treated. That figure, drawn from a global review of published cost studies, captures only the starting price of a therapy that involves ongoing expenses for years afterward. The real lifetime cost depends on choices about hardware, how often batteries need replacing, and whether the procedure ultimately reduces spending on medications and other care.

What the Initial Surgery Actually Costs

A 2024 global economic review pooled cost data from studies across multiple countries and adjusted everything to current U.S. dollars. The device alone averaged about $21,500. Surgery costs on top of the device averaged around $14,700, but that number covers only the surgical procedure itself. When you add in the full hospitalization, imaging, anesthesia, and perioperative care, the mean total surgical cost climbed to roughly $41,000. Extend the window to include the first year of follow-up visits and programming sessions, and the average reached about $47,600.¹

Those are averages with large standard deviations. Some patients in high-cost health systems faced totals well above $60,000 in the first year; others in countries with lower labor and facility costs came in under $30,000. The point is that there is no single sticker price for DBS. The device hardware is a global commodity with somewhat consistent pricing, but everything wrapped around it varies enormously by geography and institution.

The Device Is the Biggest Single Line Item

About half of the upfront surgical cost is the implantable pulse generator (IPG), the battery-powered unit placed under the skin near the collarbone. The leads that run into the brain and the extensions connecting them to the IPG add to the hardware bill, but the IPG dominates. A cost-effectiveness study of DBS for treatment-resistant obsessive-compulsive disorder found the device alone cost around $20,700 in Korea and about $15,000 in the United Kingdom, with the surgical implantation procedure adding another $7,300 to $9,600 depending on the country.²

This matters because the IPG does not last forever. Non-rechargeable batteries typically need replacement every three to five years, and each replacement means another surgery with its own hospitalization costs. That cycle of replacements is one of the biggest hidden multipliers in the long-term cost of DBS.

Rechargeable Versus Non-Rechargeable Batteries

Choosing a rechargeable IPG costs more upfront but can dramatically reduce long-term expenses. A study modeling nine years of care for dystonia patients found that rechargeable devices cut total direct medical costs by about 34% compared with non-rechargeable ones, primarily by eliminating repeated replacement surgeries. In absolute terms, the non-rechargeable path cost roughly €50,100 per patient over nine years versus about €33,300 for the rechargeable path.³

A budget-impact analysis using real-world data on Parkinson’s disease patients found even larger savings over longer horizons. Rechargeable devices with an estimated 15-year lifespan saved approximately €38,300 per patient, while next-generation devices projected to last 25 years saved around €71,600 per patient compared with standard non-rechargeable units.⁴ Each avoided replacement surgery also eliminates the infection risk, recovery time, and indirect costs that come with additional operations. For patients who need higher stimulation settings, which drain batteries faster, the rechargeable option is especially worth considering.

Medication Savings After Surgery

One of the ways DBS can offset its upfront cost is by reducing the need for expensive medications, particularly in Parkinson’s disease. Several studies have tracked this effect, and the numbers are substantial.

A 10-year follow-up study of patients who received subthalamic nucleus (STN) DBS found that their medication requirements dropped by about 31% on average and stayed reduced over the full decade. That translated to a roughly 35% decrease in medication costs. Without DBS, the researchers modeled that those same patients would have needed two to nearly three times more medication by year ten than what they actually used.⁵

In a randomized trial comparing DBS plus optimal drug therapy against drug therapy alone, the DBS group accumulated about $7,150 less in medication costs over just two years. Projected forward, that savings reached roughly $64,600 over ten years.⁶ A follow-up analysis using longer data found the five-year cumulative medication cost reduction was about $28,200 for patients who received early DBS, with projections suggesting savings topping $100,000 over 15 years of disease duration.⁷

These medication savings do not erase the surgical costs entirely, but they significantly narrow the gap. The earlier in the disease course DBS is performed, the greater the cumulative savings tend to be, because patients avoid years of escalating polypharmacy.

Total Healthcare Costs Over Five Years

Medication savings tell only part of the story. When researchers look at total healthcare spending, the picture is more complicated. A study of veterans with Parkinson’s disease found that five-year total healthcare costs were about $77,000 higher per person for DBS patients ($162,500) compared with those on medical management alone ($85,400). But when the costs of the DBS procedures themselves and their complications were stripped out, total spending was essentially the same between the two groups.⁸

That finding is worth sitting with. DBS patients did not cost the healthcare system more in terms of day-to-day medical care; the extra spending was essentially the price of the procedure and its maintenance. Meanwhile, those patients often report meaningful improvements in quality of life, reduced disability, and better motor function. Whether the extra cost is “worth it” depends on how you value those gains, which is where formal cost-effectiveness analysis comes in.

Is DBS Cost-Effective?

Health economists evaluate cost-effectiveness by calculating an incremental cost-effectiveness ratio, which compares the extra cost of a treatment against the extra health benefit it provides, measured in quality-adjusted life years (QALYs). In the United States, a treatment is generally considered cost-effective if it falls below roughly $50,000 to $100,000 per QALY gained.

For Parkinson’s disease, the evidence is fairly encouraging. A U.S.-focused analysis found that over ten years, DBS added about 1.7 QALYs compared with best medical therapy, at an incremental cost of about $23,400 per QALY. Even across multiple sensitivity analyses and a shorter five-year time horizon, the ratio stayed under $50,000 per QALY.⁹ An earlier analysis found a somewhat higher ratio of about $49,000 per QALY, still within the range considered cost-effective by conventional standards.¹⁰

For dystonia, a systematic review found an incremental cost per QALY of about $64,700, which falls in the gray zone where cost-effectiveness is debatable but not unreasonable.¹¹ For essential tremor, the same review found DBS was not cost-effective compared with focused ultrasound surgery, a newer and less invasive alternative.

For treatment-resistant obsessive-compulsive disorder, the economics depend heavily on the type of device. A 2025 analysis found that rechargeable DBS systems were reasonably cost-effective at about $41,500 to $49,400 per QALY over three to five years, while non-rechargeable systems were far more expensive per QALY gained.¹² Other studies have reported costs in the range of $34,000 to $38,000 per QALY for OCD depending on the country, placing DBS comfortably within typical willingness-to-pay thresholds.²

Does It Matter Whether You Target GPi or STN?

For Parkinson’s disease, DBS can target two brain regions: the subthalamic nucleus (STN) or the globus pallidus internus (GPi). Both are effective, and a randomized trial found that provider costs were similar between the two targets, roughly $138,000 for GPi and $132,000 for STN over the study period, a difference that was not statistically meaningful.¹³ Where the targets diverge is in medication use: patients with STN stimulation tend to reduce their medication doses more than GPi patients, and cumulative medication costs were lower for STN over 36 months.¹³ The procedural costs are a wash, but the downstream savings tilt slightly toward STN for patients whose medication burden is a major concern.

The Hidden Cost of Complications

Infection is the complication that hits the wallet hardest. When a DBS system gets infected, the typical path involves attempts to salvage the hardware through revision surgeries, and if those fail, complete removal of the device, a course of antibiotics, and then reimplantation months later once the infection clears. A study tracking these cases found the mean total cost of this sequence was about $75,500. Just over half of that went toward the reimplantation surgery. Roughly another $21,800 went to the hardware salvage attempts before explantation.¹⁴

Infection rates in DBS surgery typically range from about 1% to 10% depending on the center and the study, so while most patients never face this scenario, it represents a serious financial risk for those who do. This is one reason why choosing an experienced, high-volume surgical center matters, not just for clinical outcomes but for avoiding costly complications.

Hospital Volume and Pricing Variation

Where you get DBS surgery affects what you pay, sometimes substantially. A nationwide U.S. study of 234 hospitals over five years found that high-volume centers had considerably lower rates of high charges compared with low-volume centers (about 7% versus 15%), along with fewer prolonged hospital stays and less need for non-routine discharge.¹⁵

An earlier analysis of national inpatient data found that hospitals with smaller caseloads, private hospitals, non-teaching hospitals, and hospitals in the western United States were all independent predictors of higher costs.¹⁶ The lesson is intuitive: teams that perform DBS regularly tend to operate more efficiently, discharge patients sooner, and generate fewer complications. If you have a choice of centers, volume and academic affiliation are worth asking about.

Costs That Never Show Up on the Hospital Bill

The numbers above are direct medical costs, but DBS patients and their families face a layer of indirect expenses that are easy to overlook. A study of nearly 300 DBS patients found that travel costs for programming and follow-up visits averaged about €50 per visit, adding up to roughly €150 in the first year, €460 over five years, and more than €900 over ten years per patient-caregiver pair.¹⁷ Those figures may sound modest, but they assume relatively short distances. For patients in rural areas or countries with fewer DBS centers, the travel burden can be much larger.

Beyond travel, there are expenses that researchers have cataloged but that rarely make it into cost-effectiveness models: home modifications, assistive equipment, cleaning and gardening services for patients who can no longer manage these tasks, and lost income for both patients and their caregivers during recovery and ongoing follow-up.¹⁸ Remote programming technology, which allows clinicians to adjust DBS settings via telemedicine, has the potential to cut travel costs and time off work considerably, and several DBS manufacturers now support it.

Global Access and What Drives It

Whether a patient can access DBS at all depends heavily on their country’s economic resources, specialist workforce, and insurance infrastructure. A large multicenter study spanning 1997 to 2021 found that the strongest predictors of how many people in a given region actually received DBS were the country’s GDP per capita, the number of functional neurosurgery specialists available, and the level of insurance coverage.¹⁹ In practical terms, most DBS procedures are performed in high-income countries, and even within those countries, access varies by region. Patients in areas with fewer specialists or weaker insurance programs are less likely to receive the therapy regardless of whether it would help them.

For the same global review that produced the $48,000 first-year average, costs for Parkinson’s disease specifically were slightly higher (about $50,000 for the first year of treatment) compared to non-Parkinson’s indications (roughly $42,000), though the difference was not statistically significant.¹ The variation within each category dwarfs the difference between them, suggesting that where you get surgery matters more than what you get it for.

Focused Ultrasound as a Less Expensive Alternative

For essential tremor in particular, MRI-guided focused ultrasound (MRgFUS) has emerged as a competitor to DBS. The procedure uses focused sound waves to create a small lesion in the brain without any incision, hardware, or implant. That means no device costs, no battery replacements, and no infection risk from implanted hardware. A cost comparison in Japan found that MRgFUS saved roughly ¥400,000 (about $2,700 at current exchange rates) compared with unilateral DBS, with most of the savings coming from the procedure itself and the absence of ongoing hardware maintenance.²⁰

The trade-offs are real, though. DBS is adjustable after implantation and can be turned off or fine-tuned if problems arise. It also allows bilateral treatment, stimulating both sides of the brain, which focused ultrasound currently does not do as safely. Focused ultrasound creates a permanent lesion, so if the result is not ideal, there is limited ability to revise it.²¹ For patients with unilateral essential tremor who are not good surgical candidates, focused ultrasound can be both clinically appropriate and cheaper. For conditions like Parkinson’s disease, dystonia, and OCD, DBS remains the primary option because those conditions typically require bilateral and adjustable stimulation.